Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 85.9%

Neg 0% Neu 0% Pos 85.9%

Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.